Phase I Study of GW642444M - A Randomized, Double Blind, Placebo Controlled, Parallel-Group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects.

Trial Profile

Phase I Study of GW642444M - A Randomized, Double Blind, Placebo Controlled, Parallel-Group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Vilanterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 Aug 2009 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov (NCT00964249).
    • 25 Aug 2009 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov (NCT00964249).
    • 25 Aug 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov (NCT00964249).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top